ROIV Logo

Roivant Sciences Ltd. (ROIV) 

NASDAQ
Market Cap
$8.68B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
700 of 776
Rank in Industry
383 of 433

Largest Insider Buys in Sector

ROIV Stock Price History Chart

ROIV Stock Performance

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Insider Activity of Roivant Sciences Ltd.

Over the last 12 months, insiders at Roivant Sciences Ltd. have bought $0 and sold $130.36M worth of Roivant Sciences Ltd. stock.

On average, over the past 5 years, insiders at Roivant Sciences Ltd. have bought $20.14M and sold $529.12M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 8,000,000 shares for transaction amount of $40M was made by Dexcel Pharma Technologies Ltd. (director) on 2022‑11‑10.

List of Insider Buy and Sell Transactions, Roivant Sciences Ltd.

2024-10-21SalePresident & COO
100,000
0.0136%
$11.65$1.17M-0.34%
2024-09-26SaleDirector by Deputization
876,000
0.1177%
$11.82$10.35M-2.12%
2024-09-26Saledirector
876,000
0.1177%
$11.82$10.35M-2.12%
2024-09-25SaleDirector by Deputization
50,000
0.0067%
$11.77$588,500-1.70%
2024-09-25Saledirector
1.41M
0.1881%
$11.77$16.56M-1.66%
2024-09-25Saledirector
134,948
0.018%
$11.77$1.59M-1.66%
2024-09-24Saledirector
2.14M
0.2831%
$11.63$24.91M-0.47%
2024-09-24Saledirector
368,052
0.0486%
$11.63$4.28M-0.47%
2024-09-23SaleCEO
1.98M
0.2657%
$11.79$23.38M-2.82%
2024-09-23SaleChief Accounting Officer
250,000
0.0338%
$11.89$2.97M-2.82%
2024-02-09SalePresident & COO
96,950
0.0129%
$10.92$1.06M+3.79%
2024-01-02Sale10 percent owner
3M
0.3648%
$11.05$33.15M-1.37%
2023-10-05SaleChief Operating Officer
153,027
0.0189%
$10.11$1.55M+3.84%
2023-10-03SaleChief Operating Officer
606,221
0.0758%
$10.25$6.21M+3.74%
2023-10-02SaleChief Operating Officer
440,752
0.0581%
$10.80$4.76M+2.71%
2023-09-28Sale10 percent owner
10M
1.2883%
$12.60$126M-13.94%
2023-09-28Sale10 percent owner
8.44M
0.9967%
$11.55$97.48M-13.94%
2023-09-28Saledirector
6.9M
0.8144%
$11.55$79.65M-13.94%
2023-09-28Sale10 percent owner
10M
1.181%
$11.55$115.5M-13.94%
2023-09-28Saledirector
10M
1.181%
$11.55$115.5M-13.94%

Insider Historical Profitability

34.38%
Dexcel Pharma Technologies Ltd.director
102849443
13.9076%
$11.7430+38.38%
Oren Dan
98840843
13.3655%
$11.7410+22.38%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
SoftBank Investment Advisers$769.75M9.8973.03M0%+$07.6
Viking Global Investors$731.15M9.3969.37M0%+$00.26
QVT Financial$703.23M9.0366.72M-40.72%-$482.96M70.06
BlackRock$381.42M4.936.19M+73.93%+$162.13M0.01
Morgan Stanley$375.6M4.8235.64M+62.52%+$144.49M0.03
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.